BDP1 Antibody

What is BDP1 and what is its primary function?

BDP1 functions as a general activator of RNA polymerase III transcription. It is essential for transcription from all three types of polymerase III promoters, including those with internal promoter elements and those with promoter elements upstream of the initiation site . The protein localizes to concentrated aggregates in the nucleus and serves as a subunit of the TFIIIB transcription initiation complex, which recruits RNA polymerase III to target promoters to initiate transcription . During cell division, BDP1 is phosphorylated by casein kinase II during mitosis, resulting in its release from chromatin and suppression of polymerase III transcription . This regulatory mechanism helps control gene expression during the cell cycle.

What are the alternative nomenclature and identifiers for BDP1?

BDP1 is known by several alternative names in the scientific literature, which can cause confusion when searching databases. These alternative designations include:

• TFC5

• TFNR (Transcription factor-like nuclear regulator)

• TAF3B1

• KIAA1241

• KIAA1689

• TFIIIB90

• HSA238520

• TFIIIB150

• DKFZp686K0831

• DKFZp686C01233

• Transcription factor TFIIIB component B'' homolog

The gene accession number is NM_018429, which can be useful for specific sequence queries in genomic databases .

What types of BDP1 antibodies are available for research applications?

There are multiple types of BDP1 antibodies available for research, including:

• Mouse Monoclonal antibodies - Example: clone 2073D1a (ab74415), with IgG1 isotype

• Polyclonal Mouse IgG antibodies - Example: H00026469-B01P, reactive to human and mouse BDP1

Each antibody type offers different advantages depending on the experimental context. Monoclonal antibodies provide high specificity for a single epitope, making them suitable for targeted analysis of BDP1. Polyclonal antibodies recognize multiple epitopes and can generate stronger signals in certain applications but may have more cross-reactivity .

What are the validated applications for BDP1 antibodies?

Based on the available data, BDP1 antibodies have been validated for the following applications:

The monoclonal antibody ab74415 has been specifically tested and validated for Western blot applications with recombinant fragment samples, having a predicted band size of 294 kDa . When selecting an antibody for a specific application, it is important to check the validation status for your particular experimental system .

How is BDP1 expression altered in different cancer types?

BDP1 expression shows cancer-specific alterations that may have clinical relevance:

• Overexpressed in:

  • Breast cancer (versus normal tissue)

  • Colorectal cancer (p = 2.07 × 10^-5, 105 patients)

  • Castrate-resistant metastatic prostate cancer (p = 2.60 × 10^-11)

• Underexpressed in:

  • Lymphoma (p = 8.37 × 10^-7, 131 patients)

  • Specifically in Burkitt's lymphoma (p = 1.54 × 10^-11)

  • ALK+ anaplastic large cell lymphoma (ALCL)

• Variable expression in:

  • Kidney cancer (both over- and underexpression observed)

These expression patterns suggest tissue-specific roles for BDP1 in oncogenesis and tumor progression, with particular significance in hematological malignancies .

What are the clinical implications of BDP1 expression in lymphomas?

BDP1 expression has significant clinical relevance in specific lymphoma subtypes:

In activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL), decreased BDP1 expression correlates with poor clinical outcomes, including:

• Higher recurrence rates at 1 year (p = 0.021) and 3 years (p = 0.005)

• Increased mortality at 1 year (p = 0.030) and 3 years (p = 0.012)

These correlations suggest that BDP1 may serve as a potential prognostic biomarker in ABC DLBCL, the most common lymphoma diagnosed in adults and one with particularly poor prognosis. The specificity of BDP1 underexpression in certain lymphoma subtypes makes it a candidate for targeted research into lymphoma pathogenesis and potential therapeutic approaches .

What transcription factors regulate BDP1 expression in cancer?

Analysis of the BDP1 promoter has identified several putative binding sites for transcription factors that are frequently deregulated in lymphomas:

• MYC - Binding sites at positions -582 and -581 relative to the transcription start site (TSS)

  • MYC and BDP1 expression are inversely correlated in ALK+ ALCL

  • This suggests MYC may repress BDP1 expression

• BCL6 - Binding sites at positions -985, -936, -384, -362, -287, -276, and -173

  • Both BCL6 and BDP1 expression are decreased in ALK+ ALCL

• E2F4 - Binding sites in the BDP1 promoter

  • E2F4 expression remains relatively unchanged in ALK+ ALCL

• KLF4 - Binding sites at positions -734, -593, -553, -459, and -291

  • May partially explain the significant decrease in BDP1 observed in subtypes of NHL

This regulatory network provides insight into the mechanisms controlling BDP1 expression in different cancer contexts, particularly in lymphoma where BDP1 is significantly underexpressed .

What are the optimal protocols for using BDP1 antibodies in Western blotting?

For optimal Western blot results with BDP1 antibodies, researchers should consider:

• Sample Preparation:

  • BDP1 is a large protein (predicted size: 294 kDa), requiring careful sample preparation

  • Use fresh samples when possible and include protease inhibitors

  • Sonicate samples to ensure complete lysis and protein extraction

• Gel Electrophoresis:

  • Use low percentage (6-8%) SDS-PAGE gels to properly resolve high molecular weight proteins

  • Load adequate protein amounts (typically 20-50 μg total protein per lane)

  • Include positive controls such as recombinant BDP1 fragments when available

• Transfer and Detection:

  • Employ wet transfer methods for large proteins

  • Use PVDF membranes for better retention of high molecular weight proteins

  • Block with 5% non-fat dry milk or BSA in TBST

  • Incubate with primary antibody at manufacturer-recommended dilutions

  • Use appropriate HRP-conjugated secondary antibodies and enhanced chemiluminescence detection

When using monoclonal antibodies like ab74415, researchers should expect a predicted band size of 294 kDa. Validation data shows successful detection of recombinant fragment corresponding to the immunizing peptide .

How can researchers assess BDP1 expression in clinical samples?

For clinical sample analysis of BDP1 expression, multiple approaches can be employed:

• Protein-level analysis:

  • Immunohistochemistry (IHC) using validated BDP1 antibodies on tissue microarrays

  • Western blotting of tissue lysates

  • Flow cytometry for hematological malignancies

• mRNA expression analysis:

  • Quantitative RT-PCR for BDP1 transcript levels

  • RNA-seq for comprehensive transcriptome analysis

  • In situ hybridization for spatial expression assessment

• Correlation with clinical parameters:

  • Compare BDP1 expression with clinicopathological features

  • Perform survival analyses (as demonstrated for ABC DLBCL)

  • Assess co-expression with known biomarkers (e.g., MYC, BCL6)

Research has demonstrated that integrating BDP1 expression data with clinical outcomes can provide valuable prognostic information, particularly in ABC DLBCL where decreased BDP1 expression correlates with recurrence and mortality at 1 and 3 years .

What controls should be included when studying BDP1 in cancer research?

Proper controls are essential for reliable BDP1 research in cancer studies:

• Positive controls:

  • Cell lines with known BDP1 expression (based on literature)

  • Recombinant BDP1 protein fragments

  • Tissues with verified high BDP1 expression (e.g., colorectal cancer samples)

• Negative controls:

  • Isotype control antibodies for immunodetection methods

  • siRNA/shRNA knockdown of BDP1 to verify antibody specificity

  • Tissues with low BDP1 expression (e.g., certain lymphoma subtypes)

• Methodological controls:

  • Parallel analysis of housekeeping genes/proteins for normalization

  • Multiple antibody validation using different clones

  • Assessment of related TFIIIB complex components for pathway validation

• Clinical correlation controls:

  • Include multiple cancer subtypes to assess specificity (e.g., ABC DLBCL vs. other lymphoma types)

  • Correlate with established biomarkers (MYC, BCL6, KLF4)

  • Analyze expression in normal vs. tumor tissue from the same patient when possible

How does BDP1 contribute to cancer progression at the molecular level?

The molecular mechanisms by which BDP1 influences cancer progression appear to involve its core function in RNA polymerase III transcription:

• Regulation of tRNA and small RNA synthesis:

  • BDP1, as part of the TFIIIB complex, controls the expression of tRNAs and other small RNAs

  • Altered tRNA pools can affect translational efficiency and protein synthesis rates

  • This may influence the production of oncoproteins and tumor suppressors

• Transcriptional network interactions:

  • BDP1 expression correlates with established oncogenic transcription factors

  • Inverse correlation with MYC in ALK+ ALCL suggests regulatory interaction

  • Correlation with FOXP1 and BCL6 in lymphomas indicates integration in broader transcriptional networks

• Cell cycle influence:

  • BDP1 is phosphorylated by casein kinase II during mitosis

  • This leads to its release from chromatin and suppression of polymerase III transcription

  • Dysregulated BDP1 may therefore affect cell cycle progression

The significant underexpression of BDP1 in lymphomas and its correlation with poor clinical outcomes in ABC DLBCL suggest a potential tumor suppressor role in these contexts, warranting further investigation into therapeutic implications .

What are emerging research directions for BDP1 in precision oncology?

Based on current knowledge about BDP1, several promising research directions emerge:

• Biomarker development:

  • Validation of BDP1 as a prognostic biomarker in ABC DLBCL

  • Investigation of BDP1 expression in other cancer types with variable expression

  • Integration of BDP1 with other biomarkers for improved risk stratification

• Therapeutic targeting:

  • Exploration of approaches to modulate BDP1 expression or activity

  • Investigation of synthetic lethality between BDP1 status and other targetable pathways

  • Development of therapies addressing the downstream effects of altered BDP1 expression

• Mechanistic studies:

  • Further characterization of the BDP1 promoter regulation by oncogenic transcription factors

  • Identification of BDP1-dependent gene expression programs in different cancer contexts

  • Analysis of BDP1's role in therapy resistance mechanisms

• Multi-omics integration:

  • Correlation of BDP1 expression with genomic alterations, epigenetic modifications, and proteome changes

  • Investigation of BDP1's influence on the cancer metabolome through altered tRNA pools

  • Development of integrated models predicting cancer outcomes based on BDP1 status combined with other molecular features

These research directions hold potential to translate the observed correlations between BDP1 expression and clinical outcomes into actionable insights for cancer diagnosis, prognosis, and treatment.